Peptidream Inc. 4587
TSE · Japan · Health Technology
¥1,076.00-57.00 (-5.03%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Boost ROI with question-led libraries, reproducible synthesis, validated assays, interoperable data, AI feedback loops, partnerships, and early planning for IP, regulation, supply and talentDublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Cyclic Peptide Library Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global cyclic peptide library market, projected to grow from USD 3.75 billion in 2026 to USD 9.86 billion by 2032
KAWASAKI, Japan, July 02, 2026--PeptiDream Inc. ("PeptiDream"), a public biopharmaceutical company based in Kawasai, Japan, focused on the discovery and development of peptide-based therapeutics, announced the appointment of three new Executive Vice Presidents, strengthening its leadership team to support the PeptiDream’s continued growth and transformation into a global discovery and development company.
KAWASAKI, Japan, June 11, 2026--Completion of patient dosing in the registrational Phase 2 clinical trial of 64Cu-PSMA-I&T —a PET radiopharmaceutical targeting PSMA
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.